|
CHD8 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.13094036544726E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.96760007865305E-10 |
| Normal-vs-Stage2 |
3.769300E-04 |
| Normal-vs-Stage3 |
1.41459954861034E-10 |
| Normal-vs-Stage4 |
2.85039991609892E-10 |
| Stage1-vs-Stage2 |
2.289800E-01 |
| Stage1-vs-Stage3 |
1.512640E-01 |
| Stage1-vs-Stage4 |
2.960400E-02 |
| Stage2-vs-Stage3 |
3.631900E-02 |
| Stage2-vs-Stage4 |
1.099520E-02 |
| Stage3-vs-Stage4 |
4.710400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.86000112481588E-11 |
| Normal-vs-AfricanAmerican |
7.082400E-03 |
| Normal-vs-Asian |
2.40840000054199E-07 |
| Caucasian-vs-AfricanAmerican |
1.136360E-01 |
| Caucasian-vs-Asian |
9.880200E-01 |
| AfricanAmerican-vs-Asian |
1.171160E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.48590029169782E-10 |
| Normal-vs-Female |
1.03150044061806E-10 |
| Male-vs-Female |
3.806800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.60760002479543E-09 |
| Normal-vs-Age(41-60Yrs) |
4.07040001704218E-09 |
| Normal-vs-Age(61-80Yrs) |
7.25300042248023E-10 |
| Normal-vs-Age(81-100Yrs) |
4.593600E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.068600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.761600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.619600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.284600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.660600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.076600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.037800E-03 |
| Classical-VS-Follicular |
3.305600E-01 |
| Classical-VS-Other |
1.914800E-01 |
| Classical-VS-Normal |
7.33910043848596E-10 |
| Tall-VS-Follicular |
4.991700E-02 |
| Tall-VS-Other |
8.861200E-01 |
| Tall-VS-Normal |
2.97949998007141E-10 |
| Follicular-VS-Other |
4.639800E-01 |
| Follicular-VS-Normal |
3.50850000052638E-07 |
| Other-VS-Normal |
1.558830E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.69140002004298E-09 |
| Normal-vs-N1 |
3.17309956088252E-10 |
| N0-vs-N1 |
3.098000E-02 |
|
|
